Aurisco(SH:605116)2024-08-28 07:33Financial Performance - The company's operating revenue for the first half of 2024 reached ¥730,657,004.56, representing a 32.21% increase compared to ¥552,649,994.24 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was ¥188,592,080.74, a significant increase of 96.66% from ¥95,897,090.93 in the previous year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥187,113,195.53, up 96.97% from ¥94,998,174.60 in the same period last year[13]. - The net cash flow from operating activities was ¥167,321,378.96, reflecting a 13.38% increase from ¥147,572,652.36 in the previous year[13]. - Basic earnings per share increased by 91.67% to CNY 0.46 compared to CNY 0.24 in the same period last year[14]. - The total comprehensive income for the first half of 2024 was ¥188,656,089.75, compared to ¥97,091,629.53 in the same period of 2023, indicating strong overall performance[116]. Assets and Liabilities - Total assets increased by 11.45% to ¥2,869,494,748.00 from ¥2,574,610,570.52 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company at the end of the reporting period were ¥2,079,848,423.61, a 5.71% increase from ¥1,967,585,189.70 at the end of the previous year[13]. - The total liabilities increased to ¥738,805,707.12 from ¥601,024,121.35, representing a rise of approximately 22.9%[109]. - Cash and cash equivalents decreased to ¥337,855,608.19 from ¥461,275,008.34, a decline of 26.7%[111]. - Accounts receivable increased to ¥275,601,266.43 from ¥211,664,908.80, reflecting a growth of 30.2%[111]. Research and Development - The company maintained a high investment in R&D, with total R&D expenses amounting to 65.44 million yuan, an increase of 17.04% year-on-year[37]. - The company submitted 15 new invention patent applications and received 7 new invention patents, including 1 granted in the United States[38]. - The company is focusing on developing new products and processes, including small molecule APIs, peptides, and oligonucleotide APIs[51]. Market and Sales Strategy - The company focuses on the research, production, and sales of complex active pharmaceutical ingredients and intermediates, primarily serving large international pharmaceutical companies[19]. - The sales model primarily involves exporting raw materials and intermediates, with a stable customer base due to long-term partnerships[22]. - The company plans to continue expanding its market presence through various channels, including trade shows and customer visits[22]. - The company has established a competitive brand and has received certifications from regulatory bodies such as NMPA, FDA, and WHO[20]. Environmental and Compliance - The company has been classified as a key pollutant discharge unit, with specific monitoring of wastewater and air emissions to ensure compliance with environmental standards[58]. - The company has implemented advanced wastewater treatment processes, including iron-carbon and Fenton oxidation methods[64]. - The company has received ISO 14001:2015 environmental management system certification for itself and its major subsidiaries, ensuring compliance with environmental management protocols[76]. - The company has committed to strict adherence to local government environmental, energy-saving, and safety regulations[77]. Corporate Governance and Shareholder Relations - The company has not disclosed any plans for profit distribution or capital reserve conversion during this reporting period[2]. - The actual controller and major shareholder pledge not to interfere in the company's management activities or infringe on company interests, with legal responsibilities for any violations[86]. - The company will strengthen the management of raised funds to ensure their reasonable and standardized use, actively promoting the implementation of investment projects to enhance profitability[85]. - The company commits to improving the profit distribution system and enhancing the investor return mechanism, with a focus on returning profits to shareholders when conditions permit[85]. Future Outlook - The company provided a positive outlook for the second half of 2024, projecting a revenue growth of 25%[82]. - New product launches are expected to contribute an additional 300 million in revenue by the end of 2024[82]. - Market expansion plans include entering three new international markets by Q4 2024, aiming for a 10% market share in each[82].